Disitamab vedotin targets HER2 on tumor cells; after HER2-mediated internalization, the linker releases MMAE, which binds the vinca site on beta-tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptosis (with possible bystander killing). Beta-tubulin expression alone is not the selective target of this ADC.